This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Mantle cell lymphoma (MCL)	Cyclin D1 (CCND1; BCL1); B cell lymphoma 2 (BCL-2; BCL2)	<p>Studies in cell culture suggest combining CCND1 and BCL2 inhibitors could help treat MCL. In human MCL cell lines resistant to the BCL2 inhibitor ABT-737, small interfering RNA against CCND1 increased ABT-737-induced apoptosis compared with control siRNA. In peripheral blood mononuclear cells isolated from CCND1-positive MCL patients, ABT-737 plus the CCND1 inhibitor Seliciclib decreased growth and induced apoptosis compared with ABT-737 alone. Next steps include designing new and selective inhibitors of CCND1.</p> <p>Seliciclib (R-roscovitine), from Cyclacel Pharmaceuticals Inc., is in Phase II trials to treat non-small cell lung cancer (NSCLC) and nasopharyngeal cancer.</p> <p>Onconova Therapeutics Inc.'s CCND1 inhibitor ON 013105 is in Phase I testing to treat lymphoma and in preclinical trials for MCL. At least five companies have BCL2 antagonists in clinical testing for cancer.</p> <p>ABT-737 is a research reagent from Abbott Laboratories.</p> <p>SciBX 4(31); doi:10.1038/scibx.2011.878 Published online Aug. 11, 2011</p>	Unpatented; licensing status undisclosed	<p>Beltran, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online July 11, 2011; doi:10.1073/pnas.1018941108</p> <p>Contact: Jose A. Martinez-Climent, Clinical University of Navarra, Pamplona, Spain e-mail: jamcliment@unav.es</p>